



Yukon Immunization Program Manual

Section 8 - Biological Products

Zoster Vaccine





SECTION 8 – BIOLOGICAL PRODUCTS

Contents

Varicella Zoster Vaccine (Recombinant) (SHINGRIX®)	1
--	---

2021 November	
Varicella Zoster Vaccine (Recombinant) (SHINGRIX®)	
Supplier: GlaxoSmithKline Inc.	
INDICATIONS	<p>Recommended and provided free to ❶❷❸:</p> <ul style="list-style-type: none"> • January 1, 2021 to December 5, 2021: Individuals 65-70 years of age • December 6, 2021 to December 31, 2022: Individuals 65 years of age and older • Starting January 1, 2023, the publicly funded indications will be updated to only include Yukon residents aged 65-79. <p>Recommended but not provided free to ❶❷❸❹:</p> <ul style="list-style-type: none"> • Individuals 50 years of age and older
INITIAL SERIES	2 doses given as 0.5 mL IM, 2 to 6 months apart
REINFORCEMENTS	Not indicated at this time.
ADMINISTRATION	Product needs to be reconstituted. Use the diluent provided with the vaccine. Administer the entire volume of the reconstituted product.
SEROLOGICAL TESTING	Serological testing is not recommended before or after immunization ❶
CONTRAINDICATIONS	<ol style="list-style-type: none"> 1. History of anaphylactic reaction to a previous dose of SHINGRIX, or to any component of SHINGRIX 2. Active herpes zoster infection
PRECAUTIONS	<ol style="list-style-type: none"> 1. Delay immunization of individuals with severe acute illness until recovery. 2. SHINGRIX should be used with caution in those who are pregnant or breastfeeding as there are no data on its use in these populations
VACCINE COMPONENTS	<p>Potential allergens: polysorbate 80.</p> <p>Other components: Quillaja saponaria Molinara fraction 21, 3-O-desacyl-4'-monophosphoryl lipid A, dipotassium phosphate, sodium dihydrogen phosphate dihydrate, sucrose, cholesterol, dioleoyl phosphatidylcholine, disodium phosphate anhydrous, potassium dihydrogen phosphate.</p>
ADVERSE EVENTS	<p>Local: Mild to moderate pain, redness, swelling</p> <p>Systemic: Myalgia, fatigue, headache, chills, fever, nausea, diarrhea, vomiting, stomach pain</p>

2021 November

Varicella Zoster Vaccine (Recombinant) (SHINGRIX®)

Supplier: GlaxoSmithKline Inc.

**SPECIAL
 CONSIDERATIONS**

- SHINGRIX® and diluent should be stored to maintain cold chain (2-8°C).
- It is recommended that the vaccine be administered immediately after reconstitution to minimize loss of potency. Discard reconstituted vaccine if it is not used within 30 minutes.

- ❶ SHINGRIX® is indicated for the prevention of shingles in individuals with prior chickenpox infection. Given that nearly all Canadians eligible for this vaccine will have had prior varicella exposure, even if a diagnosis of varicella cannot be recalled, routine serological testing is not recommended. There is no known safety risk associated with vaccination of healthy individuals who are varicella-susceptible. However, in the rare circumstance that an individual is known to be serologically varicella susceptible, they should be immunized with 2 doses of varicella vaccine rather than zoster vaccine.
- ❷ SHINGRIX® may be considered for immunocompromised adults on a case by case basis. Please contact the Immunization Program Manager.
- ❸ There should be an interval of at least 1 year between receipt of live zoster vaccine and administration of SHINGRIX®. There should also be an interval of at least 1 year between an episode of shingles and administration of SHINGRIX®.
- ❹ SHINGRIX® is indicated for ages 50+. Clients aged 50-64, may be eligible to pay for and/or obtain a prescription for this product as long as other indications are met.